טוען...
The Long Road to the First FDA Approved Gene Therapy: Chimeric Antigen Receptor T Cells Targeting CD19
Thirty years after initial publications of the concept of a chimeric antigen receptor (CAR), the U.S. Food and Drug Administration (FDA) approved the first anti-CD19 CAR T cell therapy. Unlike other immunotherapies such as immune checkpoint inhibitors and bispecific antibodies, CAR T cells are uniqu...
שמור ב:
| הוצא לאור ב: | Cytotherapy |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036015/ https://ncbi.nlm.nih.gov/pubmed/32014447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2019.12.004 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|